Table 1.
Characteristics of all included studies.
| Study characteristic | RSV tests with analytical time ≤30 min, n (%) | RSV tests with analytical time >30 min, n (%) | Total sub-records,a n (%) |
|---|---|---|---|
| Number of subrecords | 88 (66.2) | 45 (33.8) | 133 (100.0) |
| Commercial index testb | |||
| 3 M Rapid Detection RSV Test | 4 (4.5) | — | 4 (3.0) |
| Aries Flu A/B & RSV Assay | — | 4 (8.9) | 4 (3.0) |
| BD Veritor System RSV | 9 (10.2) | — | 9 (6.8) |
| Alere BinaxNOW RSV | 14 (15.9) | — | 14 (10.5) |
| BioFire FilmArray Respiratory 2.1 Panel | — | 4 (8.9) | 4 (3.0) |
| cobas Liat Influenza A/B & RSV Assay | 10 (11.4) | — | 10 (7.5) |
| Directigen EZ RSV | 8 (9.1) | — | 8 (6.0) |
| ePlex Respiratory Pathogen Panel | — | 3 (6.7) | 3 (2.3) |
| ID NOW RSVc | 5 (5.7) | — | 5 (3.8) |
| mariPOC Respi test | — | 4 (8.9) | 4 (3.0) |
| Panther Fusion Flu A/B/RSV Assay | — | 7 (15.6) | 7 (5.3) |
| QuickVue RSV | 4 (4.5) | — | 4 (3.0) |
| RSV Respi-Strip | 3 (3.4) | — | 3 (2.3) |
| Simplexa Flu A/B & RSV | — | 3 (6.7) | 3 (2.3) |
| Sofia RSV FIAd | 11 (12.5) | — | 11 (8.3) |
| Xpert Flu/RSV XC | 3 (3.4) | — | 3 (2.3) |
| Xpert Xpress Flu/RSV | 6 (6.8) | — | 6 (4.5) |
| Data collection | |||
| Prospective | 64 (72.7) | 19 (42.2) | 83 (62.4) |
| Retrospective | 17 (19.3) | 16 (35.6) | 33 (24.8) |
| Mixed | 7 (8.0) | 10 (22.2) | 17 (12.8) |
| Population | |||
| Adults (≥18 years) | 1 (1.1) | 6 (13.3) | 7 (5.3) |
| Children (<18 years) | 43 (48.9) | 8 (17.8) | 51 (38.3) |
| Mixed | 41 (46.6) | 25 (55.6) | 66 (49.6) |
| Not reported | 3 (3.4) | 6 (13.3) | 9 (6.8) |
| Comparator test | |||
| DFA/IFAe | 9 (10.3) | 3 (6.7) | 12 (9.0) |
| rRT-PCR | 58 (65.9) | 33 (73.3) | 91 (68.4) |
| Viral culture | 5 (5.7) | 2 (4.4) | 7 (5.3) |
| Mixed | 16 (18.2) | 5 (11.1) | 21 (15.8) |
| Otherf | 0 | 2 (4.4) | 2 (1.5) |
| Industry sponsorship | |||
| Yes | 52 (59.1) | 35 (77.8) | 87 (65.4) |
| No | 23 (26.1) | 7 (15.6) | 30 (22.6) |
| Not reported | 13 (14.8) | 3 (6.7) | 16 (12.0) |
| Majority specimen type | |||
| Nasopharyngeal aspirate or wash | 22 (25.0) | 6 (13.3) | 28 (21.1) |
| Nasopharyngeal swab | 43 (48.9) | 22 (48.9) | 65 (48.9) |
| Nasopharyngeal aspirate or swab | 1 (1.1) | 0 | 1 (0.8) |
| Nasopharyngeal specimen | 1 (1.1) | — | 1 (0.8) |
| Nasal aspirate or wash | 4 (4.5) | 1 (2.2) | 5 (3.8) |
| Nasal swab | 1 (1.1) | 0 | 1 (0.8) |
| Mixed | 16 (18.2) | 16 (35.6) | 32 (24.1) |
| Setting of patient recruitment | |||
| Emergency department | 5 (5.7) | 4 (8.9) | 9 (6.8) |
| Hospital | 35 (39.8) | 21 (46.7) | 56 (42.1) |
| Household | 0 | 1 (2.2) | 1 (0.8) |
| Outpatient | 5 (5.7) | 5 (11.1) | 10 (7.5) |
| Mixed | 37 (42.0) | 9 (20.0) | 46 (34.6) |
| Not reported | 6 (6.8) | 5 (11.1) | 11 (8.3) |
| Setting where test was performed | |||
| Clinical laboratory | 26 (29.5) | 29 (64.4) | 55 (41.4) |
| POC | 46 (52.3) | 5 (11.1) | 51 (38.3) |
| Research laboratory | 2 (2.3) | 2 (4.4) | 4 (3.0) |
| Mixed | 10 (11.4) | 0 | 10 (7.5) |
| Not reported | 4 (4.5) | 9 (20.0) | 13 (9.8) |
Where 1 article reported several relevant sensitivity and specificity values (e.g., when more than 1 index test was studied), then each set of sensitivity and specificity values was extracted as a subrecord; 77 included studies corresponded to 133 included subrecords.
Only RSV tests with ≥3 subrecords were included in the table. The following index tests had 2 supporting subrecords: CLART PneumoVir, nCounter, NxTAG-Respiratory Pathogen Panel, MultiCode-PLx Respiratory Viral Panel, QIAstat-Dx Respiratory Panel, Simprova-RV, NucliSens EasyQ Respiratory Syncytial Virus A + B assay, Thermo Electron RSV OIA kit, and Verigene Respiratory Virus Plus Nucleic Acid Test. The following index tests had 1 supporting subrecord: Allplex Respiratory Panel 1, Colloidal Gold Genesis, GenRead RSV, Humasis RSV Antigen Test, Magicplex RV Panel Real-Time Test, Prodesse ProFlu+ Assay, RSV K-SeT, Seeplex RV15 OneStep ACE Detection, Bioline RSV, Solana RSV + hMPV, Speed-Oligo RSV, TRU RSV, and Xpect RSV.
The ID NOW RSV was formerly known as the Alere i RSV.
Fluorescence immunoassay.
Direct fluorescent antibody test/immunofluorescence assay.
“Other” comparator test was the consensus result for all 3 index tests studied (i.e., a ratio of 2:1 positive to negative results was considered a positive result, and vice versa).